Brief: Longboard Pharmaceuticals Announces Positive Topline Data From Phase 1 Clinical Study Evaluating Central Nervous System Pharmacokinetics, Pharmacodynamics Of LP352 In Healthy Volunteers
05/12/2022 14:03
Dec 5 (Reuters) - Longboard Pharmaceuticals Inc
LBPH.O :
* LONGBOARD PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE DATA
FROM A
PHASE 1 CLINICAL STUDY EVALUATING CENTRAL NERVOUS SYSTEM
PHARMACOKINETICS AND PHARMACODYNAMICS OF LP352 IN HEALTHY
VOLUNTEERS
* LONGBOARD PHARMACEUTICALS INC- FAVORABLE SAFETY,
TOLERABILITY
RESULTS OBSERVED IN STUDY, WITH ADVERSE EVENTS CONSISTENT WITH
PREVIOUS CLINICAL STUDIES
Source text for Eikon: ID:nBw36BStja
Further company coverage: LBPH.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Longboard Pharmaceuticals
See all newsBrief: Longboard Pharmaceuticals Initiates Phase 3 DEEp OCEAN Study Evaluating Bexicaserin In Developmental And Epileptic Encephalopathies (DEEs)
Longboard Pharmaceuticals Inc expected to post a loss of 62 cents a share - Earnings Preview
Brief: Longboard Pharmaceuticals Under Agreement H Lundbeck Required To Pay Co Reverse Termination Fee Of $158.9 Mln In Cash
U.S. RESEARCH ROUNDUP- Cadence Design Systems, Equity Bancshares, S&P Global
Deals of the day-Mergers and acquisitions